Investing Ideas
/
Belgian Pharmaceuticals & Biotech High Return On Equity, Low Debt

Belgian Pharmaceuticals & Biotech High Return On Equity, Low Debt

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Stocks with a return on equity of over 30% and a debt to equity ratio below 1.

1 companies

Celyad Oncology

Market Cap: €13.0m

A biotechnology company, focuses on unlocking the potential of its intellectual property.

CYAD

€0.29

-34.1%